Data may be delayed — last successful sync 2026-09-26 (18 days ago). Figures reflect the most recent completed ingest.
Company profile
Arch Biopartners Inc.
OTC: ACHFF · Healthcare · Biotechnology
Canadian filerHQ Toronto, ONReports USD
#1162 of 1,417 Healthcare companies by revenuebottom-decile growth
EA Score
13DFH 10DQ —GM 2SS 53
v0.1 · 45/100 weight · provisional
↑ listing tenure, market scale · ↓ revenue growth (YoY), 3-yr revenue growth
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
-100.0%
Net income (FY)
-$1.1M
Employees
6
as of 2026-09-18
Market cap
$44.5M
as of 2026-09-18
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$00 CAD2025
Net income-$1.1M-1.6M CAD2025
Operating income-$1.1M-1.5M CAD2025
Total assets$75.1k104.5k CAD2025
Liabilities$2.9M4.0M CAD2025
Equity-$2.8M-3.9M CAD2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Arch Biopartners Inc.’s revenue?
Arch Biopartners Inc. booked $0 in FY2025 revenue, contracting 100% year over year — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
Tenax Therapeutics, Inc.49DInstil Bio, Inc.36DAnnovis Bio, Inc.32DNoveris Health Sciences Inc.——Edesa Biotech, Inc.47DNanoViricides, Inc.35DKey facts
CEORichard Gabriel Muruve
SectorHealthcare
IndustryBiotechnology
HeadquartersToronto, ON
ExchangeOTC: ACHFF
Employees6
IPO date2002-04-24
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.